Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 1326-1330, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ohta, M.
Right arrow Articles by Itoh, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ohta, M.
Right arrow Articles by Itoh, N.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2000;46:1326-1330.)
© 2000 American Association for Clinical Chemistry, Inc.

Articles

Clinical and Analytical Evaluation of an Enzyme Immunoassay for Myelin Basic Protein in Cerebrospinal Fluid

Mitsuhiro Ohta1,2,a, Kiyoe Ohta1, Jie Ma1, Juji Takeuchi1, Takahiko Saida1, Masataka Nishimura1 and Nobuyuki Itoh3

1 Clinical Research Center, Utano National Hospital, Narutaki, Ukyo-ku, Kyoto 616-8255, Japan.

2 Department of Clinical Chemistry, Kobe Pharmaceutical University, Higashinada-ku, Kobe 658-8558, Japan.

3 Department of Genetic Biochemistry, Kyoto University Graduate School of Pharmaceutical Science, Sakyo-ku, Kyoto 606-8304, Japan.
a Author for correspondence. Fax 81-78-441-7559; e-mail mohta{at}kobepharma-u.ac.jp

Background: RIA of myelin basic protein (MBP) in cerebrospinal fluid (CSF) is commonly used as a biochemical marker of demyelination in patients with multiple sclerosis (MS). Our aim was to develop a sufficiently sensitive ELISA for MBP and evaluate it clinically in patients with MS.

Methods: The ELISA used anti-bovine MBP antibody coated on plates and biotinylated anti-MBP antibody. The bound antibody complex was quantified with streptavidin-horseradish peroxidase. MBP was determined in CSF from 84 MS patients and 55 patients with other neurological diseases.

Results: The respective within- and between-assay CVs were 4.7% and 7.2% at 200 ng/L, and 6.3% and 8.8% at 2000 ng/L. The detection limit was 30 ng/L. Most of the MS patients with acute exacerbations had markedly increased MBP in the CSF. Longitudinal studies of six MS patients with recurrent exacerbation confirmed this observation. MBP concentrations from 78 MS patients, as tested with our ELISA, correlated well with those obtained by RIA (r = 0.9; P <0.01), but the detection limit of the ELISA was much lower than that of the RIA.

Conclusions: This convenient ELISA with higher sensitivity than the existing assays is a suitable routine assay that provides a diagnostic indicator of myelin breakdown in the central nervous system; moreover, it is an excellent indicator of MS disease activity.




The following articles in journals at HighWire Press have cited this article:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
J Steiner, H Bielau, H-G Bernstein, B Bogerts, and M T Wunderlich
Increased cerebrospinal fluid and serum levels of S100B in first-onset schizophrenia are not related to a degenerative release of glial fibrillar acidic protein, myelin basic protein and neurone-specific enolase from glia or neurones.
J. Neurol. Neurosurg. Psychiatry, November 1, 2006; 77(11): 1284 - 1287.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.